As Prosedis, we operate within our fundamental priorities of innovation, performance and trust.

Our pharmaceutical research and development (R&D) approach, based on the multiplier effect of "Science, Technology" elements, focuses on science with the use of advanced technologies such as functional genomics, artificial intelligence and machine learning, as well as the immune system. This approach allows us to accelerate the pace at which we develop and deliver innovative drugs, prioritize molecules that are more likely to succeed, and complete less promising programs, while also focusing on targeted drugs in areas such as oncology.

We balance active lifecycle management of our existing drugs with a solid R&D plan aimed at protecting more people by bringing our drugs to new regions. Our passion for innovation is to lead the industry by changing the way medicines are discovered, developed and manufactured. We will continue to unlock potential in new areas by focusing on accelerating the development of key R&D products and testing new technologies. With our industry-leading science, we aim to accelerate the delivery of our most promising products to patients, address the biggest unmet medical needs, and transform the world with our science.

We are working to be one of the first countries to be evaluated for planned clinical trials in any treatment field, to increase investment in research and development in Turkey, and to provide patients with early access to new treatment options.